Brief: Pharnext And Charcot-Marie-Tooth Association Announce Biomarker Research Collaboration
03/09/2020 07:39
Sept 3 (Reuters) - PHARNEXT SA PHARN.PA :
* PHARNEXT AND THE CHARCOT-MARIE-TOOTH ASSOCIATION ENTER
BIOMARKER RESEARCH COLLABORATION
* COLLABORATION FOCUSED ON IDENTIFYING AND CHARACTERIZING
KEY
BIOMARKERS IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
* RESULTS OF THIS RESEARCH COLLABORATION MIGHT INFORM THE
ADDITION
OF NEW EXPLORATORY ENDPOINTS IN NEXT PHASE III TRIAL OF PXT3003
TO BE INITIATED IN Q1 2021
Source text for Eikon: ID:nEQ9gjxdPa
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development